Single IM dose of nirsevimab reduces likelihood of hospitalization due to RSV in average-risk infants during first year of life (HARMONIE)

There's more to see -- the rest of this topic is available only to subscribers.

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.